FMR LLC and Abigail P. Johnson filed a Schedule 13G with the SEC on November 4, 2026, disclosing beneficial ownership of 13,180,206 shares of common stock in Silence Therapeutics PLC as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: FMR LLC reported 13,180,206 shares of Silence Therapeutics PLC common stock, representing 7.1% of the class.
  • Sole voting power: FMR LLC holds sole voting power over all 13,180,206 shares, with no shared voting power reported.
  • Sole dispositive power: Both FMR LLC and Abigail P. Johnson each report sole dispositive power over 13,180,206 shares.
  • Abigail P. Johnson: Listed as an individual (type IN) reporting person, with 0 sole or shared voting power but 13,180,206 shares of sole dispositive power.
  • Event date: The filing event triggering this statement occurred on September 30, 2026.
  • Third-party interest noted: According to the filing, "one or more other persons are known to have the right to receive or the power to direct the receipt of dividends," though no single other person holds more than 5% of the outstanding common stock.

FMR LLC Discloses Passive Stake in Silence Therapeutics as of September 30, 2026

FMR LLC, a Delaware-organized holding company located at 245 Summer Street, Boston, Massachusetts 02210, filed a Schedule 13G disclosing a 7.1% beneficial ownership position in Silence Therapeutics PLC (NASDAQ:SLN), a company whose principal executive offices are listed at 12 Hammersmith Grove, Office 205, London, W6 7AP. The filing was signed on November 4, 2026, by Stephanie J. Brown, acting under a power of attorney on behalf of FMR LLC and Abigail P. Johnson.

According to the filing, FMR LLC holds sole voting power and sole dispositive power over all 13,180,206 shares, with shared voting and shared dispositive power each reported as zero. Abigail P. Johnson is identified as an individual reporting person who holds no voting power but reports sole dispositive power over the same 13,180,206 shares. FMR LLC is classified as a parent holding company or control person (type HC) under the applicable rules, and Exhibit 99 is cited to identify the subsidiary that acquired the reported securities.

The filing states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." No group membership, dissolution of a group, or ownership of 5% or less of a class is indicated as applicable in this statement.

What Was Disclosed

FMR LLC and Abigail P. Johnson disclosed a combined beneficial ownership of 13,180,206 shares, equal to 7.1% of Silence Therapeutics PLC common stock, as of September 30, 2026, through a Schedule 13G filed on November 4, 2026.